Comments
Loading...

Inozyme Pharma Analyst Ratings

INZYNASDAQ
Logo brought to you by Benzinga Data
$3.95
At close: May 19 EDT
$3.94
-0.00500-0.13%
Pre-Market: 8:14 AM EDT
Q1 2025 Earnings were released on Wed May 14th, before the market open
Inozyme Pharma (INZY) announced it will be acquired by Biomarin Pharmaceutical (BMRN) on Friday, May 16, 2025 for $270.0M paid in cash
Consensus Rating1
Buy
Highest Price Target1
$30.00
Lowest Price Target1
$4.00
Consensus Price Target1
$14.08

Inozyme Pharma Analyst Ratings and Price Targets | NASDAQ:INZY | Benzinga

Inozyme Pharma Inc has a consensus price target of $14.08 based on the ratings of 12 analysts. The high is $30 issued by Piper Sandler on January 13, 2025. The low is $4 issued by Wells Fargo on May 16, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Jefferies, and Needham on May 16, 2025, respectively. With an average price target of $6.67 between Wells Fargo, Jefferies, and Needham, there's an implied 68.99% upside for Inozyme Pharma Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Jan
4
Mar
2
Apr
1
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
Jefferies
Needham
HC Wainwright & Co.
Raymond James

1calculated from analyst ratings

Analyst Ratings for Inozyme Pharma

Buy NowGet Alert
05/16/2025Buy Now1.39%Wells Fargo
Tiago Fauth42%
→ $4DowngradeOverweight → Equal-WeightGet Alert
05/16/2025Buy Now1.39%Jefferies
Ryan Deschner68%
$15 → $4DowngradeBuy → HoldGet Alert
05/16/2025Buy Now204.18%Needham
Joseph Stringer50%
$12 → $12DowngradeBuy → HoldGet Alert
05/14/2025Buy Now204.18%Needham
Joseph Stringer50%
$15 → $12MaintainsBuyGet Alert
04/10/2025Buy Now305.58%HC Wainwright & Co.
Edward White45%
$16 → $16ReiteratesBuy → BuyGet Alert
04/08/2025Buy Now280.23%Needham
Joseph Stringer50%
$15 → $15ReiteratesBuy → BuyGet Alert
03/12/2025Buy Now204.18%Raymond James
Ryan Deschner68%
$24 → $12MaintainsOutperformGet Alert
03/11/2025Buy Now483.02%Piper Sandler
Allison Bratzel62%
$30 → $23MaintainsOverweightGet Alert
03/11/2025Buy Now280.23%Needham
Joseph Stringer50%
$23 → $15MaintainsBuyGet Alert
03/11/2025Buy Now305.58%HC Wainwright & Co.
Edward White45%
$16 → $16ReiteratesBuy → BuyGet Alert
01/13/2025Buy Now660.46%Piper Sandler
Christopher Raymond53%
$43 → $30MaintainsOverweightGet Alert
01/13/2025Buy Now178.83%Wells Fargo
Tiago Fauth42%
$14 → $11MaintainsOverweightGet Alert
01/13/2025Buy Now305.58%HC Wainwright & Co.
Edward White45%
$14 → $16MaintainsBuyGet Alert
01/10/2025Buy Now305.58%HC Wainwright & Co.
Edward White45%
$14 → $16MaintainsBuyGet Alert
11/06/2024Buy Now254.88%HC Wainwright & Co.
Edward White45%
$14 → $14ReiteratesBuy → BuyGet Alert
11/06/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
10/25/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
10/25/2024Buy Now254.88%HC Wainwright & Co.
Edward White45%
$14 → $14ReiteratesBuy → BuyGet Alert
09/30/2024Buy Now280.23%Wedbush
David Nierengarten57%
$15 → $15ReiteratesOutperform → OutperformGet Alert
09/12/2024Buy Now305.58%Stifel
Dae Gon Ha46%
→ $16Initiates → BuyGet Alert
08/13/2024Buy Now330.93%Jefferies
Maury Raycroft31%
$16 → $17AssumesBuy → BuyGet Alert
08/08/2024Buy Now254.88%HC Wainwright & Co.
Edward White45%
$14 → $14ReiteratesBuy → BuyGet Alert
08/06/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
07/26/2024Buy Now280.23%Wedbush
David Nierengarten57%
$15 → $15ReiteratesOutperform → OutperformGet Alert
07/02/2024Buy Now254.88%HC Wainwright & Co.
Edward White45%
$14 → $14ReiteratesBuy → BuyGet Alert
05/30/2024Buy Now254.88%Wells Fargo
Tiago Fauth42%
→ $14Initiates → OverweightGet Alert
05/08/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now254.88%B of A Securities
Tazeen Ahmad53%
$16 → $14MaintainsBuyGet Alert
03/13/2024Buy Now305.58%HC Wainwright & Co.
Edward White45%
$16 → $16MaintainsBuyGet Alert
03/12/2024Buy Now483.02%Needham
Joseph Stringer50%
$23 → $23ReiteratesBuy → BuyGet Alert
01/30/2024Buy Now280.23%Wedbush
David Nierengarten57%
$15 → $15ReiteratesOutperform → OutperformGet Alert
11/08/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23ReiteratesBuy → BuyGet Alert
09/27/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23ReiteratesBuy → BuyGet Alert
09/08/2023Buy Now280.23%Wedbush
David Nierengarten57%
→ $15MaintainsOutperformGet Alert
08/09/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23ReiteratesBuy → BuyGet Alert
08/08/2023Buy Now305.58%HC Wainwright & Co.
Edward White45%
→ $16ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now305.58%HC Wainwright & Co.
Edward White45%
$19 → $16MaintainsBuyGet Alert
07/27/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23Reiterates → BuyGet Alert
04/19/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23Reiterates → BuyGet Alert
03/23/2023Buy Now52.09%Jefferies
Suji Jeong26%
$4.5 → $6UpgradeHold → BuyGet Alert
03/23/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23Reiterates → BuyGet Alert
02/17/2023Buy Now406.97%HC Wainwright & Co.
Edward White45%
→ $20Reiterates → BuyGet Alert
02/17/2023Buy Now483.02%Needham
Joseph Stringer50%
→ $23Reiterates → BuyGet Alert
05/26/2022Buy Now26.74%Jefferies
Suji Jeong26%
→ $5Initiates → HoldGet Alert

FAQ

Q

What is the target price for Inozyme Pharma (INZY) stock?

A

The latest price target for Inozyme Pharma (NASDAQ:INZY) was reported by Wells Fargo on May 16, 2025. The analyst firm set a price target for $4.00 expecting INZY to rise to within 12 months (a possible 1.39% upside). 26 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Inozyme Pharma (INZY)?

A

The latest analyst rating for Inozyme Pharma (NASDAQ:INZY) was provided by Wells Fargo, and Inozyme Pharma downgraded their equal-weight rating.

Q

When was the last upgrade for Inozyme Pharma (INZY)?

A

The last upgrade for Inozyme Pharma Inc happened on March 23, 2023 when Jefferies raised their price target to $6. Jefferies previously had a hold for Inozyme Pharma Inc.

Q

When was the last downgrade for Inozyme Pharma (INZY)?

A

The last downgrade for Inozyme Pharma Inc happened on May 16, 2025 when Wells Fargo changed their price target from N/A to $4 for Inozyme Pharma Inc.

Q

When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on May 16, 2025 so you should expect the next rating to be made available sometime around May 16, 2026.

Q

Is the Analyst Rating Inozyme Pharma (INZY) correct?

A

While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a downgraded with a price target of $0.00 to $4.00. The current price Inozyme Pharma (INZY) is trading at is $3.95, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch